EGCG also decreased the levels of free fatty acids and TNF-α in the serum and the expression of TNF-α, IL-6, IL-1β, and IL-18 mRNAs in the liver, indicating that it prevents obesity-related liver tumorigenesis by inhibiting the IGF/IGF-1R axis, improving hyperinsulinemia, and attenuating chronic inflammation [103]. Here, IGF1 is linked to obesity disorder.